RPG Life Sciences Limited (RPGLIFE) AI Stock Analysis

• Market Cap: ₹38.62B
• Dividend Yield: 0.85%
• Average Volume (3M): 3.23K
• Price to Earnings (P/E): 17.9
• Beta (1Y): 0.87
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IN
• Employees: 1,270
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 22.28
• Shares Outstanding: 16,539,015
• 10 Day Avg. Volume: 8,652
• 30 Day Avg. Volume: 3,228
• PEG Ratio: 0.19
• Price to Book (P/B): 7.03
• Price to Sales (P/S): 5.71
• P/FCF Ratio: 89.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 76 Outperform
• Price Target: ₹2,617.00 ▲(13.61% Upside)

The score is driven primarily by strong financial performance—high and improving margins and a near debt-free balance sheet—tempered by weaker cash-flow conversion versus reported earnings. Technical signals are broadly neutral, and valuation looks reasonable on P/E but with a modest dividend yield.

RPG Life Sciences Limited Business Overview & Revenue Model

Company Description

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, anti-spasmodic, etc. It also provides generics primarily in area of immunosuppressant therapy; and finished dosage formulations for various therapies, such as nephrology, rheumatology, oncology, gastroenterology, cardiovascular, diabetology, orthopedics, neuropsychiatry, respiratory, nutritional, general, urology, anti-diabetic, anti-dengue, vitamins and minerals, gynecology and pediatrics, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.

How the Company Makes Money

RPG Life Sciences Limited Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.57B	6.53B	5.77B	5.09B	4.37B	3.83B
Gross Profit	4.38B	4.39B	3.93B	1.70B	2.87B	2.46B
EBITDA	1.39B	1.60B	1.36B	1.08B	902.40M	718.40M
Net Income	1.83B	1.83B	876.60M	676.40M	514.80M	400.00M
Balance Sheet
Total Assets	0.00	6.58B	5.13B	4.19B	3.45B	3.03B
Cash, Cash Equivalents and Short-Term Investments	2.65B	2.66B	1.26B	1.15B	698.00M	403.60M
Total Debt	0.00	0.00	0.00	100.00K	9.40M	20.20M
Total Liabilities	-5.31B	1.27B	1.38B	1.12B	888.40M	869.40M
Stockholders Equity	5.31B	5.31B	3.75B	3.08B	2.56B	2.16B
Cash Flow
Free Cash Flow	0.00	418.30M	251.30M	580.90M	408.00M	497.60M
Operating Cash Flow	0.00	778.60M	943.60M	908.20M	647.50M	582.70M
Investing Cash Flow	0.00	-418.00M	-791.50M	-1.06B	-346.60M	-79.60M
Financing Cash Flow	0.00	-270.80M	-203.10M	-171.20M	-135.10M	-104.90M

RPG Life Sciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPGLIFE	76 Outperform	₹38.62B	17.93	―	0.85%	―	―
ORCHPHARMA	64 Neutral	₹37.00B	70.81	―	―	-9.23%	-56.08%
AARTIDRUGS	57 Neutral	₹35.15B	17.65	―	0.24%	4.08%	31.52%
GUFICBIO	57 Neutral	₹32.08B	56.36	―	0.03%	7.78%	-34.68%
MOREPENLAB	57 Neutral	₹21.46B	21.76	―	0.49%	-0.29%	-29.04%
UNICHEMLAB	54 Neutral	₹29.22B	33.03	―	―	25.42%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

RPG Life Sciences Limited Corporate Events

RPG Life Sciences Forms Wholly Owned Subsidiary RPG Active Pharma

RPG Life Sciences Limited has incorporated a wholly owned subsidiary named RPG Active Pharma Limited, which was officially registered on December 24, 2025, under a new corporate identification number issued by the Ministry of Corporate Affairs. The move, disclosed under SEBI’s Listing Regulations, signals a further structuring of the group’s pharma operations and could provide a dedicated vehicle for future growth initiatives within active pharmaceutical or related businesses, offering greater strategic and operational flexibility for the company and its stakeholders.

RPG Life Sciences Unveils Strategic Leadership and Expansion Plans

RPG Life Sciences Limited announced significant strategic decisions following a board meeting on December 15, 2025. The company appointed Mr. Amol Lone as the new Chief Financial Officer, enhancing its leadership with his extensive experience in corporate finance and strategic decision-making. Additionally, the company plans to incorporate a wholly owned subsidiary, RPG Active Pharma Limited, to focus on the API business. This move includes transferring its existing API operations to the new entity and investing up to Rs.105 crore to support its growth and operations, signaling a strategic shift to strengthen its market position in the pharmaceutical sector.

RPG Life Sciences Releases Q2 FY26 Earnings Call Transcript

RPG Life Sciences Limited has released the transcript of its Q2 FY26 earnings call, held on October 17, 2025. The transcript, which details the company’s unaudited financial results for the period ending September 30, 2025, is now available on their website. This release provides stakeholders with insights into the company’s financial performance and strategic direction.

RPG Life Sciences Addresses Unusual Trading Volume

RPG Life Sciences Limited has experienced a significant increase in trading volume, prompting the National Stock Exchange of India to seek clarification. The company responded by stating there are no undisclosed events or information affecting its operations or performance, and it remains committed to transparency by regularly updating the stock exchanges with any price-sensitive information.

RPG Life Sciences Sees Surge in Trading Volume

RPG Life Sciences Limited has experienced a significant increase in trading volume, prompting the Exchange to seek further information from the company to ensure investor interests are protected. The company’s response is still pending, leaving the market and stakeholders awaiting further clarification on the implications of this development.